
CLAIMS

1. A compound of the general formula (I) or a salt or a physiologically functional derivative thereof,



formula (I)

wherein

the substituent $-Y-R^1$ is attached to the 5- or 6-position of the benzazole;

X independently represents S, O, SO, or SO_2;

Y independently represents S, O, NR^2, SO, or SO_2;

A independently represents $\leftarrow CO-$, $\leftarrow CS-$, $\leftarrow SO-$, $\leftarrow SO_2-$, $\leftarrow CO_2-$, $\leftarrow CONR^8-$, $\leftarrow NR^8CO-$, $\leftarrow NR^8CONR^9-$; $\leftarrow NR^8COO-$, $\leftarrow NR^8NR^9CO-$, $\leftarrow NR^8OCO-$, $\leftarrow ONR^8CO-$, or $\leftarrow NR^8SO_2-$, where $\leftarrow$ indicates the point of attachment to R^3;

R^2 independently represents H, alkyl, cycloalkyl, $-COR^6$, $-SOR^6$, $-SO_2R^6$, -CN, hydroxyalkyl, haloalkyl, or haloalkyloxy;

R^3 independently represents H, alkyl, cycloalkyl, aryl, or heteroaryl;

R^4 independently represents H, $-COR^6$, $-CO_2R^6$, $-SOR^6$, $-SO_2R^6$, $-SO_3R^6$, $-NO_2$, -CN, $-CF_3$, $-OCH_3$, $-OCF_3$, alkyl, cycloalkyl, alkoxy, $-NH_2$, alkylamino, $-NR^7COR^6$, halogen, -OH, -SH, alkylthio, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^5 independently represents H, alkyl, cycloalkyl, $-COR^6$, $-SOR^6$, $-SO_2R^6$, -CN, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, or heteroaryl;

R^{6a} independently represents H, alkyl, cycloalkyl, $-NR^8NR^2R^9$, $-ONR^8R^9$, $-NR^8OR^9$, aryl or heteroaryl;


R^6 independently represents H, alkyl, cycloalkyl, $-NR^8R^9$, $-NR^8NR^2R^9$, $-ONR^8R^9$, $-NR^8OR^9$, aryl or heteroaryl;

R^7 independently represents H, alkyl, cycloalkyl, or alkoxy;

R^8 independently represents H, alkyl, cycloalkyl, $-COR^6$, $-SOR^6$, $-SO_2R^6$, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^9 independently represents H, alkyl, cycloalkyl, -COR^6, -SOR^6, -SO_2R^6, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^1 independently represents one of the following groups:



where * indicates the point of attachment;

Z independently represents O, NR^8, or S;

R^{12} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, -$NR^{8a}R^{9a}$, or -X^2R^{16};

R^{8a} independently represents H, alkyl, cycloalkyl, -COR^{6a}, -SOR^6, -SO_2R^6, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^{9a} independently represents H, alkyl, cycloalkyl, -COR^{6a}, -SOR^6, -SO_2R^6, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^{13} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, -$NR^{8a}R^{9a}$, or -X^2R^{16};

R^{14} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, -$NR^{8a}R^{9a}$, or -X^2R^{16};


R^{15} independently represents H, halogen, nitro, trifluoromethyl, alkyl,


aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;

R^{17} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;

X^2 independently represents a direct bond, -O-, $-CH_2-$, -OCO-, carbonyl, -S-, -SO-, $-SO_2-$, $-NR^8CO-$, $-CONR^8-$, $-SO_2NR^8-$, $-NR^8SO_2-$ or $-NR^{8a}-$;

R^{16} independently represents H, alkyl, cycloalkyl, $-SOR^6$, $-SO_2R^6$, $-OCH_3$, hydroxyalkyl, haloalkyl, haloalkyloxy, or one of the following groups:





where * indicates the point of attachment;

m independently represents an integer from 1-3;

L is absent or represents a divalent linkage group selected from alkylen, cycloalkylen, heterocyclylen, arylen, or heteroarylen, wherein one or more of the (-CH_2-) groups may be replaced by an oxygen or a NR^8, and wherein one or more carbon atoms may be independently substituted by one or two substituents selected from halogen, hydroxy, alkoxy, halo-alkyloxy, phoshonooxy, or phoshonooxyalkyl;

X^3 independently represents –COOH, -COOalkyl, -OH, -SH, -SO_3H, or -$SO_2NR^8R^9$;

R^{18} independently represents H, phosphonooxy, or phosphonooxyalkyl;

R^{19} independently represents H, alkyl, cycloalkyl, alkylamino, or alkoxy;

with the proviso that the following compounds are excluded: N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-2-phenyl-acetamide, N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-benzothiazol-2-yl]-2-phenyl-acetamide, N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-3-phenyl-propionamide, N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzo-thiazol-2-yl]-2-(3-trifluoromethyl-phenyl)-acetamide, 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-acet-amide, 2-(2-chloro-5-trifluoromethyl-phenyl)-N-[6-(6,7-dimethoxy-quinolin-4-yl-oxy)-5-fluoro-benzothiazol-2-yl]-acetamide;

wherein an alkyl group, if not stated otherwise, denotes a linear or branched C_1-C_6-alkyl, preferably a linear or branched chain of one to five carbon atoms, a linear or branched C_2-C_6-alkenyl or a linear or branched C_2-C_6-alkynyl group, which can be substituted by one or more substituents R`;

wherein R` independently represents H, -CO_2R``, -CONHR``, -CR``O, -$SO_2$NR``, -NR``-CO-haloalkyl, -$NO_2$, -NR``-SO_2-haloalkyl, -NR``-$SO_2$-alkyl, -$SO_2$-alkyl, -NR``-CO-alkyl, -CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy, aryl, arylalkyl or heteroaryl;

wherein R`` independently represents H, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, heteroaryl or aminoalkyl;

wherein a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, preferably four to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group E, E being O, S, SO, SO_2, N, or NR``, R`` being as defined above;

wherein an alkoxy group denotes an O-alkyl group, the alkyl group being as defined above; the alkoxy group is preferably a methoxy, ethoxy, isopropoxy, *t*-butoxy or pentoxy group;

wherein an alkylthio group denotes an S-alkyl group, the alkyl group being as defined above;

wherein an haloalkyl group denotes an alkyl group which is substituted by one to five halogen atoms, the alkyl group being as defined above;

wherein a hydroxyalkyl group denotes an HO-alkyl group, the alkyl group being as defined above;

wherein a haloalkyloxy group denotes an alkoxy group which is substituted by one to five halogen atoms, the alkyl group being as defined above;

wherein a hydroxyalkylamino group denotes an $(HO\text{-alkyl})_2$-N- group or HO-alkyl-NH- group, the alkyl group being as defined above;


wherein an alkylamino group denotes an HN-alkyl or N-dialkyl group, the alkyl group being as defined above;

wherein a halogen group is chlorine, bromine, fluorine or iodine;

wherein an aryl group denotes an aromatic group having five to fifteen carbon atoms, which can be substituted by one or more substituents R`, where R` is as defined above;

wherein a heteroaryl group denotes a 5- or 6-membered heterocyclic group which contains at least one heteroatom like O, N, S. This heterocyclic group can be fused to another ring. This heterocyclic group can be substituted by one or more substituents R`, wherein R` is as defined above.

2. The compound of claim 1 or a salt or a physiologically functional derivative thereof, wherein R^1 is (* indicates the point of attachment)



3. The compound according to claim 1 or a salt or a physiologically functional derivative thereof, wherein X independently represents S or O; Y represents NH; A represents –CO-; R^5 represents H.


4. The compound according to claim 1 or a salt or a physiologically functional derivative thereof, wherein X independently represents S or O; Y represents NH; R^5 represents H. A represents ←NHCO-, where ← indicates the point of attachment to R^3;

5. The compound according to any one of the claims 1 to 4 or a salt or a physiologically functional derivative thereof, wherein the -Y-R^1 substituent is attached to the 6-position of the benzazole.

6. The compound according to claim 5 or a salt or a physiologically functional derivative thereof, wherein R^{12} and R^{15} are H, and R^{13} and R^{14} independently

represent -O-alkyl which may be substituted.

7. A compound of the general formula (Ia) or a salt or a physiologically functional derivative thereof,



formula (Ia)

wherein


the substituent $-Y^a-R^{1a}$ is attached to the 5- or 6-position of the benzazole;

X^a independently represents S, O, SO, or SO_2;

Y^a independently represents S, NR^2, SO, or SO_2;


A^a independently represents ←CO-, ←CS-, ←SO-, ←SO_2-, ←CO_2-, ←$CONR^8$-, ←NR^8CO-, ←NR^8CONR^9-; ←NR^8COO-, ←NR^8NR^9CO-, ←NR^8OCO-, ←ONR^8CO-, or ←NR^8SO_2-, where ← indicates the point of attachment to R^3;

R^{1a} independently represents one of the following groups:



where * indicates the point of attachment;

R^{11} independently represents H, $-NHR^{8a}$, or one of the groups:




where * indicates the point of attachment;

R^{13a} independently represents H, halogen, nitro, trifluoromethyl, alkyl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;

R^2, R^3, R^4, R^5, R^6, R^{6a}, R^7, R^8, R^{8a}, R^9, R^{9a}, R^{12}, R^{13}, R^{16}, or X^2, are as defined in claims 1-6.

8. A compound of the general formula (II) or a salt or a physiologically functional derivative thereof,



formula (II)

wherein

the substituent $-Y^b-$ is attached to the 5- or 6-position of the benzazole;

X^b independently represents S, O, SO, or SO_2;

Y^b independently represents S, NR^2, SO, or SO_2;

A^b independently represents $\leftarrow CO-$, $\leftarrow CS-$, $\leftarrow SO-$, $\leftarrow SO_2-$, $\leftarrow CO_2-$, $\leftarrow CONR^8-$, $\leftarrow NR^8CO-$, $\leftarrow NR^8CONR^9-$; $\leftarrow NR^8COO-$, $\leftarrow NR^8NR^9CO-$, $\leftarrow NR^8OCO-$, $\leftarrow ONR^8CO-$, or $\leftarrow NR^8SO_2-$, where $\leftarrow$ indicates the point of attachment to R^3;

R^{4b} independently represents H, $-SOR^6$, $-SO_2R^6$, $-SO_3R^6$, $-NO_2$, -CN, $-CF_3$, $-OCH_3$, $-OCF_3$, alkyl, cycloalkyl, alkoxy, oxyalkyl, alkoxyalkyl, $-NH_2$, alkylamine, aminoalkyl, alkylaminoalkyl, $-NR^7COR^6$, halogen, -OH,

-SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;
R^2, R^3, R^5, R^6, R^{6a}, R^7, R^8, R^{8a}, R^9, R^{9a}, R^{11}, R^{12}, R^{16}, X^2 are as defined in claims 1 to 6.

9. A compound according to any one of claims 1 to 8 or a salt or physiologically functional derivative thereof for the use as a medicament.

10. A compound according to any one of claims 1 to 8 or a salt or physiologically functional derivative thereof for the use in therapy.

11. A composition containing a compound of any one of claims 1 to 8 or a salt or physiologically functional derivative thereof.


12. A composition according to claim 11 containing an adjuvant and/or and additive.

13. The use of a compound according to any one of claims 1 to 10 or a salt or a physiologically functional derivative thereof or a composition according to claim 11 or 12 for the preparation of a pharmaceutical composition for the treatment of diseases which are cured or relieved by the inhibition of one ore several kinases.

14. The use of a compound according to any one of claims 1 to 10 or a salt or a physiologically functional derivative thereof or a composition according to claim 11 or 12 for the preparation of a medicament for treating, relieving, and/or preventing cancer.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A compound of the general formula (I) or a salt thereof,



formula (I)

wherein

the substituent $-Y-R^1$ is attached to the 5- or 6-position of the benzazole;

X independently represents S, O, SO, or SO_2;

Y independently represents S, NR^2, SO, or SO_2;

A independently represents $\leftarrow CO-$, $\leftarrow CS-$, $\leftarrow SO-$, $\leftarrow SO_2-$, $\leftarrow CO_2-$, $\leftarrow CONR^8-$, $\leftarrow NR^8CO-$, $\leftarrow NR^8CONR^9-$, $\leftarrow NR^8COO-$, $\leftarrow NR^8NR^9CO-$, $\leftarrow NR^8OCO-$, $\leftarrow ONR^8CO-$, or $\leftarrow NR^8SO_2-$, where $\leftarrow$ indicates the point of attachment to R^3;

R^2 independently represents H, alkyl, cycloalkyl, $-COR^6$, $-SOR^6$, $-SO_2R^6$, -CN, hydroxyalkyl, haloalkyl, or haloalkyloxy;

R^3 independently represents H, alkyl, cycloalkyl, aryl, or heteroaryl;

R^4 independently represents H;

R^5 independently represents H;


R^{6a} independently represents H, alkyl, cycloalkyl, $-NR^8NR^2R^9$, $-ONR^8R^9$, $-NR^8OR^9$, aryl or heteroaryl;

R^6 independently represents H, alkyl, cycloalkyl, aryl or heteroaryl;

R^8 independently represents H, alkyl, cycloalkyl, $-COR^6$, $-SOR^6$, $-SO_2R^6$, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^9 independently represents H, alkyl, cycloalkyl, $-COR^6$, $-SOR^6$, $-SO_2R^6$, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^1 independently represents one of the following groups:



where * indicates the point of attachment;

Z independently represents O, NR^8, or S;

R^{12} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;

R^{8a} independently represents H, alkyl, cycloalkyl, $-COR^{6a}$, $-SOR^6$, $-SO_2R^6$, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^{9a} independently represents H, alkyl, cycloalkyl, $-COR^{6a}$, $-SOR^6$, $-SO_2R^6$, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R^{13} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;

R^{14} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;


R^{15} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;


R^{17} independently represents H, halogen, nitro, trifluoromethyl, alkyl, aryl, heteroaryl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$;

X^2 independently represents a direct bond, -O-, $-CH_2-$, -OCO-, carbonyl, -S-, -SO-,

$-SO_2-$, $-NR^8CO-$, $-CONR^8-$, $-SO_2NR^8-$, $-NR^8SO_2-$ or $-NR^{8a}-$;

R^{16} independently represents H, alkyl, cycloalkyl, $-SOR^6$, $-SO_2R^6$, $-OCH_3$, hydroxyalkyl, haloalkyl, haloalkyloxy, or one of the following groups:





where * indicates the point of attachment;

m independently represents an integer from 1-3;

L is absent or represents a divalent linkage group comprising alkylene, cycloalkylene, heterocyclylene, arylene, or heteroarylene, wherein one or more of the (-CH_2-) groups may be replaced by an oxygen or a NR^8, and wherein one or more carbon atoms may be independently substituted by one or two substituents, wherein each substituent is halogen, hydroxy, alkoxy, halo-alkyloxy, phoshonooxy, or phoshonooxyalkyl;

X^3 independently represents –COOH, -COOalkyl, -OH, -SH, -SO_3H or -$SO_2NR^8R^9$;

R^{18} independently represents H, phosphonooxy, or phosphonooxyalkyl;

R^{19} independently represents H, alkyl, cycloalkyl, alkylamino, or alkoxy;

with the proviso that the following compounds are excluded: N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-2-phenyl-acetamide, N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-benzothiazol-2-yl]-2-phenyl-acetamide, N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-3-phenyl-propionamide, N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-2-(3-trifluoromethyl-phenyl)-acetamide, 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-acetamide, 2-(2-chloro-5-trifluoromethyl-phenyl)-N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-acetamide;

wherein an alkyl group, if not stated otherwise, denotes a linear or branched C_1-C_6-alkyl, a linear or branched C_2-C_6-alkenyl or a linear or branched C_2-C_6-alkynyl group, which can be substituted by one or more substituents R';

wherein R' independently represents H, -CO_2R", -CONHR", -CR"O, -SO_2NR", -NR"-CO-haloalkyl, -NO_2, -NR"-SO_2-haloalkyl, -NR"-SO_2-alkyl, -SO_2-alkyl, -NR"-CO-alkyl, -CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy, aryl, arylalkyl or heteroaryl;

wherein R" independently represents H, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, heteroaryl or aminoalkyl;

wherein a cycloalkyl group denotes a non-aromatic ring system containing three to eight carbon atoms, wherein one or more of the carbon atoms in the ring can be substituted by a group E, E being O, S, SO, SO_2, N, or NR", R" being as defined above;

wherein an alkoxy group denotes an O-alkyl group, the alkyl group being as defined above;

wherein an alkylthio group denotes an S-alkyl group, the alkyl group being as defined above;

wherein an haloalkyl group denotes an alkyl group which is substituted by one to five halogen atoms, the alkyl group being as defined above;

wherein a hydroxyalkyl group denotes an HO-alkyl group, the alkyl group being as defined above;

wherein a haloalkyloxy group denotes an alkoxy group which is substituted by one to five halogen atoms, the alkyl group being as defined above;

wherein a hydroxyalkylamino group denotes an $(HO\text{-alkyl})_2$-N- group or HO-alkyl-NH- group, the alkyl group being as defined above;

wherein an alkylamino group denotes an HN-alkyl or N-dialkyl group, the alkyl group being as defined above;

wherein a halogen group is chlorine, bromine, fluorine or iodine;

wherein an aryl group denotes an aromatic group having five to fifteen carbon atoms, which can be substituted by one or more substituents R', wherein R' is as defined above;

wherein a heteroaryl group denotes a 5- or 6-membered heterocyclic group which contains at least one heteroatom, wherein the heterocyclic group can be fused to another ring, and wherein the heterocyclic group can be substituted by one or more substituents R', wherein R' is as defined above.


2. The compound according to claim 1, wherein alkyl is C_1-C_5 alkyl.

3. The compound according to claim 1 or 2, wherein the cycloalkyl group comprises four to eight carbon atoms.

4. The compound according to claim 1, 2 or 3, wherein alkoxy is methoxy, ethoxy, isopropoxy, t-butoxy or pentoxy.

5. The compound according to any one of claims 1 to 4, wherein the heteroatom in the heteroaryl group is O, N or S.

6. The compound according to any one of claims 1 to 5, or a salt thereof, wherein R^1 is




7. The compound according to any one of claims 1 to 6, or a salt thereof, wherein X independently represents S or O; Y represents NH; A represents -CO-; and R^5 represents H.

8. The compound according to any one of claims 1 to 6, or a salt thereof, wherein X independently represents S or O; Y represents NH; R^5 represents H; and A represents ←NHCO-.

9. The compound according to any one of claims 1 to 8, or a salt thereof, wherein the -Y-R^1 substituent is attached to the 6-position of the benzazole.

10. The compound according to any one of claims 1 to 9, or a salt thereof, wherein when present R^{12} and R^{15} are H, and R^{13} and R^{14} independently represent -O-alkyl which may be substituted.

11. A compound of the general formula (Ia) or a salt thereof,



formula (Ia)

wherein


the substituent $-Y^a-R^{1a}$ is attached to the 5- or 6-position of the benzazole;

X^a independently represents S, O, SO, or SO_2;

Y^a independently represents S, NR^2, SO, or SO_2;


A^a independently represents ←CO-, ←CS-, ←SO-, ←SO_2-, ←CO_2-, ←$CONR^8$-, ←NR^8CO-, ←NR^8CONR^9-, ←NR^8COO-, ←NR^8NR^9CO-, ←NR^8OCO-, ←ONR^8CO-, or ←NR^8SO_2-, where ← indicates the point of attachment to R^3;

R^{1a} independently represents one of the following groups:



where * indicates the point of attactment;

R^{11} independently represents H, -NHR^{8a}, or one of the groups:




where * indicates the point of attachment;

R^{13a} independently represents H, halogen, nitro, trifluoromethyl, alkyl, $-NR^{8a}R^{9a}$, or $-X^2R^{16}$; and

R^2, R^3, R^4, R^5, R^6, R^{6a}, R^8, R^{8a}, R^9, R^{9a}, R^{12}, R^{13}, R^{16}, or X^2, are as defined in any one of claims 1 to 10.

12. A compound of the general formula (II) or a salt thereof,



formula (II)

wherein

the substituent $-Y^b-$ is attached to the 5- or 6-position of the benzazole;

X^b independently represents S, O, SO, or SO_2;

Y^b independently represents S, NR^2, SO, or SO_2;

A^b independently represents $\leftarrow CO-$, $\leftarrow CS-$, $\leftarrow SO-$, $\leftarrow SO_2-$, $\leftarrow CO_2-$, $\leftarrow CONR^8-$, $\leftarrow NR^8CO-$, $\leftarrow NR^8CONR^9-$, $\leftarrow NR^8COO-$, $\leftarrow NR^8NR^9CO-$, $\leftarrow NR^8OCO-$, $\leftarrow ONR^8CO-$, or $\leftarrow NR^8SO_2-$, where $\leftarrow$ indicates the point of attachment to R^3;

R^{4b} independently represents H;

R^2, R^3, R^5, R^6, R^{6a}, R^8, R^{8a}, R^9, R^{9a}, R^{11}, R^{12}, R^{16}, X^2 are as defined in any one of claims 1 to 10.

13. The compound according to any one of claims 1 to 12, or a salt thereof, for use as a medicament for the treatment or prevention of a disease characterized by proliferation of keratinocytes, T-cells or both.

14. The compound according to claim 13, wherein the disease is an inflammatory or immune disorder which is Addison's disease, alopecia areata, Ankylosing spondylitis, haemolytic anemia, pernicious anemia, aphthae, aphthous stomatitis, arthritis, arteriosclerotic disorders, osteoarthritis, rheumatoid arthritis, aspermiogenese, asthma bronchiale, auto-immune asthma, auto-immune hemolysis, Bechet's disease, Boeck's disease, inflammatory bowel disease, Burkitt's lymphoma, Crohn's disease, chorioiditis, colitis ulcerosa, Coeliac disease, cryoglobulinemia, dermatitis herpetiformis, dermatomyositis, insulin-dependent type I diabetes, juvenile diabetes, idiopathic diabetes insipidus, insulin-dependent diabetes mellisis, autoimmune demyelinating diseases, Dupuytren's contracture, encephalomyelitis, encephalomyelitis allergica, endophthalmia phacoanaphylactica, enteritis allergica, autoimmune enteropathy syndrome, erythema nodosum leprosum, idiopathic facial paralysis, chronic fatigue syndrome, febris rheumatica, glomerulo nephritis, Goodpasture's syndrome, Graves' disease, Harnman-Rich's disease, Hashimoto's disease, Hashimoto's thyroiditis, sudden hearing loss, sensoneural hearing loss, hepatitis chronica, Hodgkin's disease, haemoglobinuria, paroxysmatica, hypogonadism, ileitis regionalis, iritis, leucopenia, leucemia, lupus erythematosus disseminatus, systemic lupus erythematosus, cutaneous lupus erythematosus, lymphogranuloma malignum, mononucleosis infectiosa, myasthenia gravis, traverse myelitis, primary idiopathic myxedema, nephrosis, ophthalmia symphatica, orchitis granulomatosa, pancreatitis, pemphigus, pemphigus vulgaris, polyarteritis nodosa, polyarthritis chronica primaria, polymyositis, polyradiculitis acuta, psoriasis, purpura, pyoderma gangrenosum, Quervain's thyreoiditis, Reiter's syndrome, sarcoidosis, ataxic sclerosis, progressive systemic sclerosis, scleritis, sclerodermia, multiple sclerosis, sclerosis disseminata, acquired spenic atrophy, infertility due to antispermatozoan antibodies, thrombocytopenia, idiopathic thrombocytopenia purpura,

thymoma, acute anterior uveitis, vitiligo, AIDS, HIV, SCID, Epstein Barr virus associated diseases, virus associated B cell lymphoma, parasitic disease, or immunesuppressed disease states.

15. The compound according to claim 14, wherein the immunesuppressed disease states are viral infections following allograft transplantations, AIDS, cancer, chronic active hepatitis diabetes, toxic shock syndrome or food poisoning.

16. The compound according to any one of claims 1 to 12, or a salt thereof, for use in the treatment of cell proliferation disorders; the prophylaxis of immunological diseases and conditions; the treatment of diseases caused by malignant cell proliferation; the support of cell generation poiesis; the therapeutic control of tissue generation and degeneration; the therapeutic modification of cell and tissue maintenance; or blood cell homeostasis.

17. The compound according to claim 16, wherein the diseases and conditions are cancer, lymphomas or solid tumors.

18. The compound according to claim 17, wherein the cancer is leukemia or myeloma.

19. The compound according to claim 17 or 18, wherein the lymphomas are Hodgkin's or non-Hodgkin's lymphoma.

20. The compound according to any one of claims 17 to 19, wherein the solid tumors are breast, prostate, liver, bladder, lung, esophageal, stomach, colorectal, genitourinary, gastrointestinal, skin, pancreatic, brain, uterine, colon, head and neck, ovarian, melanoma, astrocytoma, small cell lung cancer, glioma, basal and squameous cell carcinoma, sarcomas or osteosarcoma.

21. A pharmaceutical composition comprising the compound as defined in any one of claims 1 to 12, or a salt thereof, together with a pharmaceutically acceptable diluent or carrier.

22. The pharmaceutical composition according to claim 21, for the treatment, relief or prevention of cancer.

23. Use of the compound as defined in any one of claims 1 to 12, or a salt thereof, in the preparation of a medicament for the treatment, relief or prevention of cancer.